Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial - PubMed
4 hours ago
- #IgA nephropathy
- #clinical trial
- #Atrasentan
- Atrasentan reduced proteinuria at an interim analysis and after 2.5 years of treatment in patients with IgA nephropathy.
- The main stratum showed a trend toward slower eGFR decline with atrasentan compared to placebo, but the difference at week 136 was not statistically significant (p=0.057).
- Atrasentan significantly improved eGFR preservation when used alongside SGLT2 inhibitors compared to placebo alone.
- The safety profile of atrasentan was similar to placebo, with balanced treatment-emergent adverse events and no new safety signals identified.
- Fluid retention events occurred at a comparable rate between atrasentan and placebo groups in the main stratum.